Gene Transfer Clinical Study in Crigler-Najjar Syndrome (VALENS)

VALENS: A Phase 1/2, Randomized, Open-Label, Ascending-Dose, Delayed-Treatment Concurrent Control Clinical Study to Evaluate the Safety and Preliminary Efficacy of AT342, an AAV8-Delivered Gene Transfer Therapy in Crigler-Najjar Syndrome Subjects Aged 1 Year and Older

This is a Phase 1/2, multinational, open-label, ascending-dose, delayed-treatment concurrent control clinical study to evaluate the safety and preliminary efficacy of AT342 in subjects with Crigler-Najjar aged ≥1 year. Subjects will receive a single dose of AT342 and will be followed for safety and efficacy for 5 years.

Study Overview

• Status: Terminated
• Conditions: Crigler-Najjar Syndrome
• Intervention / Treatment: Genetic: AT342

Detailed Description

This study will evaluate safety and preliminary efficacy of gene transfer in Crigler Najjar Syndrome. Subjects will receive a single dose of AT342 delivered intravenously. A maximum of 3 dose levels of AT342 are planned for evaluation in this study. Up to four subjects will be enrolled at each dose level including up to 1 subject at each dose level randomized to control with delayed administration of the investigational product. Dose escalation to the next dose level will be considered after evaluation of at least 4 weeks of data from subjects dosed at the current dose level. One of the dose levels will be chosen for dose expansion, and the chosen dose will be administered to all delayed-treatment control subjects.

The primary efficacy endpoint measure of change in total serum bilirubin will be assessed at weeks 12 (whilst still on phototherapy) and week 18 (after phototherapy has been weaned) after administration of AT342; and the primary efficacy endpoint measure of change in number of hours of phototherapy will be assessed at week 18

This study will utilize an independent Data Monitoring Committee that will monitor subject safety and provide recommendations to Audentes regarding dose escalation, dose expansion, and safety matters.

At study termination, only one (1) pediatric participant was enrolled. This study was intended to be a Phase 1/2 trial but the study never moved forward to Phase 2.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Phase 1

Contacts and Locations

Study Locations

• Israel
  • Jerusalem, Israel, 9103102
    • Shaare Zedek Medical Center
• United Kingdom
  • London, United Kingdom, SE9 9RS
    • King's College Hospital NHS Foundation Trust
• United States
  • New York
    • Bronx, New York, United States, 10467
      • Children's Hospital at Montefiore
  • Pennsylvania
    • Strasburg, Pennsylvania, United States, 17579
      • Clinic for Special Children

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

• Subject has a diagnosis of Crigler-Najjar syndrome resulting from a confirmed mutation in the UGT1A1 gene as assessed by a Sponsor-approved testing facility.
• Subject is aged ≥1 year.
• Subject is prescribed daily phototherapy for a minimum of 6 hours within a 24-hour period (daily illumination time).

Key Exclusion Criteria:

• Subject is currently participating in an interventional study or has received gene or cell therapy.
• Subject has received a whole liver, partial liver, or hepatocyte transplant; or subject has a liver transplant scheduled within the treatment period of this study.
• Subject has significant cholestatic disease at screening.
• Subject is receiving phenobarbital or other known inducer of UGT1A1 within 30 days of screening.
• Subject tests positive for AAV8 neutralizing antibodies with titers above protocol specified threshold.
• Other than as required per protocol, subject has received immune-modulating agents within 3 months before dosing (use of inhaled corticosteroids to manage chronic respiratory conditions is allowed); use of other concomitant medications to manage chronic conditions must have been stable for at least 4 weeks before dosing.
• Subject has any clinically significant laboratory values, in the opinion of the investigator.
• Subject has clinically significant underlying liver disease (other than CN) at screening.
• Subject has a history of, or currently has, a clinically important condition other than CN, in the opinion of the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Cohort 1; 1.5 x 10^12 vg/kg of AT342 delivered intravenously one time	Genetic: AT342; AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
Experimental: Cohort 2; 6.0 x 10^12 vg/kg of AT342 delivered intravenously one time	Genetic: AT342; AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
Experimental: Cohort 3; 1.5 x 10^13 vg/kg of AT342 delivered intravenously one time	Genetic: AT342; AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
No Intervention: Delayed-Treatment Control; Control subjects will generally have the same assessments as treated subjects. Once the optimal dose is selected, control subjects will undergo pre-treatment baseline procedures to confirm that they are eligible to receive treatment with AT342. Once eligible control subjects are dosed with AT342, they will initiate the same post-dose procedures as subjects who received AT342.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Treatment-emergent adverse events (safety and tolerability)	Adverse events, serious adverse events, and laboratory abnormalities (including immunological parameters)	Baseline to Week 24
Total serum bilirubin	Change in total serum bilirubin	Baseline to Week 12 (on phototherapy) and Baseline to Week 18 (off phototherapy)
Hours of Phototherapy	Change in number of hours of daily phototherapy (daily illumination time)	Baseline to Week 18

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phototherapy	Proportion of subjects with successful weaning off of phototherapy	Baseline to Week 18
UGT Protein	Change in Liver UGT protein expression, DNA, and RNA levels	24 Weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Quality of Life Assessment: Pediatric Quality of Life Inventory (PedsQL)	Change in quality of life assessment	Baseline to Week 18
Caregiver Burden Assessment: Family Impact Module Scores	Change in Burden of Disease score	Baseline to Week 18
Clinical Global Impression of Severity and of Improvement	Change in Investigator assessment of disease severity and improvement	Baseline to Week 18

Collaborators and Investigators

• Sponsor: Audentes Therapeutics
• Investigators: Study Director: Suyash Prasad, M.D., Audentes Therapeutics

Study record dates

Study Major Dates

• Study Start (Actual): September 8, 2017
• Primary Completion (Actual): February 11, 2021
• Study Completion (Actual): February 11, 2021

Study Registration Dates

• First Submitted: July 17, 2017
• First Submitted That Met QC Criteria: July 18, 2017
• First Posted (Actual): July 21, 2017

Study Record Updates

• Last Update Posted (Actual): May 18, 2022
• Last Update Submitted That Met QC Criteria: May 12, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Adeno Associated Virus; CN; Crigler-Najjar; AAV8 Delivered Gene Transfer
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Metabolic Diseases; Disease; Genetic Diseases, Inborn; Metabolism, Inborn Errors; Hyperbilirubinemia, Hereditary; Syndrome; Cardiomyopathies; Crigler-Najjar Syndrome
• Other Study ID Numbers: AT342-02

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No